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STATEMENT OF INTEREST OF AMICUS CURIAE1 
The patents at issue in this lawsuit were granted on two genes related to 
breast cancer and ovarian cancer and on all ways of looking at those genes to 
determine if a person has a predisposition to cancer.  These patents, exclusively 
licensed to Myriad, violate the religious principle of Amicus Curiae that the human 
body and its parts should not be owned, a belief akin to the legal principle that 
products of nature, laws of nature and natural phenomena are not subject matter 
eligible for patent protection.  And, significantly, because the gene patents at issue 
cover everyone’s BRCA1 and BRCA2 genes, the patents put the members of the 
Amicus Curiae in the untenable position of being personally subject to patents that 
violate their religious beliefs. 
Amicus Curiae The Southern Baptist Convention is America’s largest 
non-Catholic denomination with more than 16.2 million members in over 44,000 
churches nationwide.  Southern Baptists hold the belief that the genetic code 
should not be owned.  Southern Baptist Convention, Resolution on the Patenting of 
Animal and Human Genes (June 1995), available at http://www.sbc.net/ 
resolutions/amResolution.asp?ID=570.  
                                                 
1 The Parties have consented to the filing of this brief.  No part of this brief was 
authored by counsel for any Party.  No Party, Party’s counsel, or person other than 
the Amicus Curiae, its members, or its counsel contributed money that was 
intended to fund preparing or submitting the brief.     
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SUMMARY OF ARGUMENT 
 The patenting of human genes is an affront to humanity.  The possibility of 
obtaining a patent on a person’s genes also encourages physicians and researchers 
to treat people in a dehumanizing way.   For many people, the patenting of genes 
also violates their religious beliefs. 
 The patent system exists to encourage invention.  But, in the case at bar, 
Myriad did not invent the breast cancer genes, their sequences, or the correlations 
between certain mutations in those gene sequences and breast cancer.  Yet patents 
on the gene sequences and correlations have been improperly issued.   
 Basic principles of patent law provide that products of nature and laws of 
nature are unpatentable subject matter.  Whether viewed from the secular belief 
that gene sequences and correlations are part of the prior art created by nature—or 
from the religious belief that they were created by a divine Creator—the result is 
the same.  Amicus Curiae the Southern Baptist Convention urge this Court to 
uphold the District Court’s decision and invalidate the Myriad patent claims at 
issue.   
 
 3 
ARGUMENT 
I.  Upholding Myriad’s Patent Claims Would be Harmful to All 
Individuals, No Matter What Their Religious Beliefs 
 
The patenting of human genetic sequences conflicts with the unique nature 
of Homo sapiens.  “So God created man in His own image, in the image of God He 
created him . . ..”  Genesis 1:27.  Human life is sacred and possesses unique value 
derived from the Creator.  This Judeo-Christian belief that each person is created 
by God in His own image is the root of the U.S. legal system’s reverence for the 
individual.  Theodosius Dobzhansky, The Pattern of Human Evolution, in The 
Uniqueness of Man 45 (J. Roslansky ed., 1969).  This reverence for the individual 
as the result of divine origin is expressed in the Declaration of Independence: “We 
hold these truths to be self-evident, that all men are created equal, and that they are 
endowed by their Creator with certain unalienable rights . . ..”  This concept is 
present in Anglo-American jurisprudence implicit in the old English law notion of 
man as liber et legalis homo (a free and lawful man).  Norman St. John-Stevas, 
Law and the Moral Consensus, in Life or Death: Ethics and Options 44 (D. Labby 
ed., 1968); Francis Pizzulli, Asexual Reproduction and Genetic Engineering: A 
Constitutional Assessment of the Technology of Cloning, 47 S. Cal. L. Rev. 476, 
507-508 (1974).  
The U.S. legal system protects the individual in many ways, such as through 
the fundamental constitutional right to personal privacy.  This case presents this 
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Court with the opportunity to protect the intrinsically unique value derived from 
our divine origin by finding Myriad’s patents on our genetic material to be invalid. 
The patenting of human genetic material attempts to wrest ownership from 
God and commodifies human biological materials and, potentially, human beings 
themselves.  Human beings are pre-owned.  We belong to the sovereign Creator.  
We are, therefore, not to be killed without adequate justification (e.g., in self-
defense) nor are we, or our body parts, to be bought and sold in the marketplace.  
The image of the Creator pervades human life in all of its parts.  Furthermore, the 
right to own one part of a human being is the right to own all the parts of a human 
being.  This right must not be transferred from the Creator to a company.  See 
generally Richard D. Land & C. Ben Mitchell, Patenting Life: No, 63 First Things 
16, 20-22 (1996). 
Beyond the harm of usurping the Creator’s role, transferring the rights of 
ownership of human beings from the Creator to Myriad has caused harm in the 
health care setting.  Myriad’s patents on gene sequences (products of nature) and 
correlations (laws of nature) grant the company the ability to prevent others from 
providing testing for mutations in the BRCA1 and BRCA2 gene sequences that are 
associated with a higher risk for breast cancer.  Breast cancer is a serious health 
issue for women across the U.S., where one in eight women in the United States 
will develop breast cancer before they are ninety-five.  Sean Altekruse et al., SEER 
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Cancer Statistics Review, 1975-2007, National Cancer Institute (2010), available 
at http://seer.cancer.gov/csr/1975_2007/.  However, Myriad’s patents on gene 
sequences and correlations prevent women from receiving affordable BRCA1 and 
BRCA2 testing and from receiving second opinions.  Second opinions are 
particularly important because women base crucial surgical decisions on the results 
of these tests.  Further, Myriad does not screen for all mutations associated with 
breast cancer, so some women may receive results that indicate that Myriad does 
not know whether the mutation causes breast cancer or not, causing anxiety which 
may lead to needless prophylactic surgeries such as mastectomies (removal of 
breasts) or oophorectomies (removal of ovaries).  Stifling or Stimulating – The 
Role of Gene Patents in Research and Genetic Testing: Hearing Before the 
Subcomm. on Cts., the Internet and Intell. Prop. of the H. Judicary Comm., 110th 
Cong. 47 (2007) (statement of Dr. Wendy Chung).  See also Lori B. Andrews, The 
Gene Patent Dilemma: Balancing Commercial Incentives With Health Needs, 2 
Hous. J. of Health L. and Pol’y 65 (2002).   
None of these harms needs to occur.  There are sound legal grounds to 
invalidate the patent claims at issue and this Court should do so. 
Beyond the harm to patients in the health care setting, allowing patents on 
genes diminishes the humanity of all of us.  Such patents commodify humans and 
profoundly alter the relationship between individuals and researchers, turning 
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people into treasure troves due to possibility of patenting products of nature from 
people’s bodies.   
After John Moore’s surgery for hairy cell leukemia, his doctor kept asking 
him to return to provide samples of blood, sperm, bone marrow, and other tissue.  
Moore v. Regents of the Univ. of Cal., 793 P.2d 479 (Cal. 1990).  Without Moore’s 
knowledge or consent, his doctor created a cell line from Moore’s tissue, named it 
the Mo cell line, patented it, and then sold rights to the cell line to a biotechnology 
firm.  Id.  
 When Moore found out that his cells were U.S. Pat. No. 4,438,032, he felt 
that his integrity had been violated, his body exploited, and his tissue turned into a 
product:  “My doctors are claiming that my humanity, my genetic essence, is their 
invention and their property.  They view me as a mine from which to extract 
biological material.  I was harvested.”  John Vidal & John Carvel, Lambs to the 
Gene Market, The Guardian, Nov. 12, 1994, at 25. 
When the California Supreme Court considered the issue, it ruled that Moore 
could not sue for theft of his property (his cells), but that his right to informed 
consent had been violated.  Justice Mosk dissented from the majority’s grant to the 
doctor and a biotechnology company of a property right in the patient’s tissue.  
Justice Mosk noted that “our society acknowledges a profound ethical imperative 
to respect the human body as the physical and temporal expression of the unique 
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human persona.”  Moore v. Regents of the Univ. of Cal., 793 P.2d 479, 515-516 
(Cal. 1990) (Mosk, J. dissenting).  He reviewed previous exploitations of the 
human body that have been since abolished—slavery, indentured servitude, and 
debtor’s prison—and stated:   
Yet their specter haunts the laboratories and boardrooms of today’s 
biotechnological research-industrial complex. It arises wherever 
scientists or industrialists claim, as defendants claim here, the right to 
appropriate and exploit a patient’s tissue for their sole economic 
benefit—the right, in other words, to freely mine or harvest valuable 
physical properties of the patient’s body. . ..  “Such research tends to 
treat the human body as a commodity—a means to a profitable end. 
The dignity and sanctity with which we regard the human whole, body 
as well as mind and soul, are absent when we allow researchers to 
further their own interests without the patient’s participation by using 
a patient’s cells as the basis for a marketable product.”   
 
Id. at 515-516 (citation omitted).   
And harvest they do.  For over a decade, Ashkenazi Jewish families of 
children with Canavan disease and non-profit foundations provided tissue and 
money to a geneticist so that he could sequence the genetic mutation that caused 
this devastating neurological disease.  Greenberg v. Miami Children’s Hosp. 
Research Inst., Inc., 264 F. Supp. 2d 1064 (S.D. Fla. 2003). 
The families intended that the genetic sequence be used to develop a genetic 
test, so couples could be tested to see if they were carriers of a gene mutation that 
might affect their children. They had contacted this particular geneticist because he 
had been active in Tay-Sachs screening, where inexpensive genetic testing was 
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undertaken in schools and synagogues, as well as in doctors’ offices, to alert 
Ashkenazi Jewish individuals to their risk of having a child with that disorder.  Id.  
When the doctor identified the gene sequence, though, he and his hospital 
patented it without the knowledge or consent of the tissue sources.  And when the 
families and non-profit foundations convinced medical providers to offer Canavan 
gene testing for free, the hospital with the patent shut down the free testing.  
Lucinda Hahn, Owning a Piece of Jonathon, Chicago Magazine 83, 88-89 (May 
2003).  When the families and foundations sued, the Southern District of Florida 
held that the plaintiffs had no property right to their tissue.  However, the court 
ruled they could maintain a cause of action for unjust enrichment since “the facts 
paint a picture of a continuing research collaboration that involved Plaintiffs also 
investing time and significant resources in the race to isolate the Canavan gene.”  
Id. at 1073-74. 
Research on people’s body parts to find genes—often without the 
individuals’ informed consent—is common but violates medical ethics tenets and 
many individuals’ religious beliefs.  Court cases have recognized that a patient’s 
religious beliefs should be taken into consideration in determining what is proper 
handling of their bodies and their body parts.  See, e.g., Lott v. State of N.Y., 225 
N.Y.S.2d 434 (Ct. Cl. 1962); Kohn v. U.S., 591 F. Supp. 568 (E.D.N.Y. 1984). 
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In the Orthodox Jewish community, for example, unauthorized use of body 
tissue violates religious beliefs which require that the body be buried whole.  If a 
person’s leg is amputated during his or her life, arrangements are made to store that 
body part for burial with the individual after death.  Henry Fitzgerald, Jr., Woman 
Awarded $1.25 Million in Suit; Funeral Home Must Compensate for Losing 
Mother’s Amputated Legs, Sun-Sentinel (Fort Lauderdale), May 16, 1997, at 1B.  
Yet a pathologist removed Albert Einstein’s brain after his death and undertook 
research seeking a gene for aneurysm without prior consent from Einstein or his 
family members.  Rabbis have asked the pathologist for Einstein’s brain so that it 
could be buried, allowing the scientist to rest in peace.  Lori Andrews & Dorothy 
Nelkin, Body Bazaar:  The Market for Human Tissue in the Biotechnology Age 9-
16 (Crown Publishers 2001). 
Within a year of the granting of the first BRCA1 gene patent to Myriad’s 
assignors, the Southern Baptist Convention adopted a resolution denouncing the 
patenting of human genes.  Southern Baptist Convention, Resolution on the 
Patenting of Animal and Human Genes (June 1995), available at 
http://www.sbc.net/resolutions/amResolution.asp?ID=570.  The Southern Baptist 
Convention holds the belief that “[m]arketing human life is a form of genetic 
slavery.  Instead of whole persons being marched in shackles to the market block, 
human gene sequences are labeled, patented, and sold to the highest bidders.  That 
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researchers and biotechnology companies are applying for the patents clearly 
signals the shocking direction of current genetic technology.  That the U.S. Patent 
Office would grant such applications is absolutely chilling.”  Southern Baptist 
Convention, BRCA – Statement of Support from the Ethics & Religious Liberty 
Commission, Southern Baptist Convention, May 12, 2009, available at 
http://www.aclu.org/free-speech/brca-statement-support-ethics-religious-liberty-
commission-southern-baptist-convention.  See also Richard D. Land & C. Ben 
Mitchell, Patenting Life: No, 63 First Things 16 (1996).   
The World Council of Churches brings together 349 churches, 
denominations and church fellowships in more than 110 countries and territories 
throughout the world, representing over 560 million Christians.  Just as the 
Southern Baptist Convention opposes gene patenting, “[t]he World Council of 
Churches is opposed to the buying and selling of human body parts.  This includes 
the patenting of human genes.  The dignity of the human person is irreconcilable 
with any commodification of human life.  Human life is commodified when its 
value is weighed against another value.  This is what happens when human life is 
patented.  Such patenting gives power over human life to specific human beings 
that cannot be justified.  Life ultimately belongs to God.  The patenting of human 
life is in opposition to this conviction.”  World Council of Churches, Genetic, 
Agriculture and Human Life, document from the Justice, Peace and Creation 
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Team, approved by WCC Executive Committee Porto Alegre, Brazil, General 
Assembly Feb. 2006. 
 The United Methodist Church, too, has spoken out against gene patents.  “In 
1995, we organized a campaign of religious leaders calling for an end to the 
patenting of life, and the building blocks of life, including genes.  In the 
intervening years, we have been dismayed that tests for the presence of genes 
associated with some diseases like cancer have been controlled in the US by a few 
organizations.  This is not the case in Europe where the United Methodist Church 
has many local congregations, but it is sadly still the case in the US.”  United 
Methodist Church, BRCA Statement of Support: United Methodist Board of 
Church and Society, May 12, 2009, available at http://www.aclu.org/free-
speech/brca-statement-support-united-methodist-board-church-and-society.    
For Judaism, “the fundamental issue here is whether human genes, even 
mutated, ‘isolated’ or ‘purified’ human genes are ‘natural,’ i.e., part of nature.  
Generally speaking, genes and genetic sequences have been treated by the courts 
and PTO not as human body-parts or as human tissue, but much like other 
chemical compositions that are patentable.  However, Jewish legal ethics would 
take the position that as either natural entities or as ‘extensions of nature,’ human 
DNA and human genes are part of nature, not ‘man-made,’ not merely a chemical, 
and therefore ineligible to become patented entities protected by a property right.”  
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Rabbi Byron L. Sherwin, Ph.D, Patents and Patients: Human Gene Patenting and 
Jewish Legal Ethics, available at http://www.thehumanfuture.org/commentaries/ 
gene_patents/genepatents_commentaries_sherwin01.pdf.    
As Rabbi Sherwin notes, gene patenting raises “the specter of genetic 
discrimination and evokes memories of the demonic eugenic social policies of 
Nazi Germany during the Holocaust.  Indeed, references to the Holocaust have 
been evoked by some of the most articulate opponents of the patenting of human 
tissues and human genes.  For example, the eminent biologist, Erwin Chagroff, has 
discussed the sometimes predatory and exploitative practices of the biotech and 
pharmaceutical industries to secure monopolistic patents on human genes and 
tissues as ‘an Auschwitz in which valuable enzymes, hormones, and so on will be 
extracted instead of gold teeth.’”  Id. (citation omitted).   
Amicus Curiae the Southern Baptist Convention support genetic research to 
address the 4,000 genetic diseases.  But, in the words of the Ethics & Religious 
Liberty Commission of the Southern Baptist Convention, “while we have been 
generally supportive of the advance of genetic science, lauding its potential for 
good, we are equally concerned about the potential for abuses. We view the 
patenting of human genes as a particularly egregious abuse of genetic technology.”  
Southern Baptist Convention, BRCA – Statement of Support from the Ethics & 
Religious Liberty Commission, Southern Baptist Convention, May 12, 2009, 
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http://www.aclu.org/free-speech/brca-statement-support-ethics-religious-liberty-
commission-southern-baptist-convention.   
Appellant Myriad and its Amici BIO and PhRMA argue that gene patenting 
is an economic necessity to encourage the discovery of genes.2  Appellants’ Br. 3-
4, 12; BIO Br. 24-25; PhRMA Br. 15-18.  The same arguments were made by 
plantation owners about how slavery was an economic necessity.  As with slavery, 
some entities (such as Myriad) benefit economically.  But the benefit to certain 
companies is not worth the medical, personal, and religious harms to us all.   
Gene patents are an affront from both a secular and a religious viewpoint.  
Upholding the District Court’s decision in this case would be beneficial to all 
humankind. 
II. Gene Sequences and Correlations Between Gene Sequences and Cancer 
are Unpatentable Subject Matter Under 35 U.S.C. § 101 and Under 
Article I, Section 8, Clause 8 of the U.S. Constitution 
 
A long line of patent law precedents has held that products of nature and 
laws of nature are not patentable subject matter under 35 U.S.C. § 101 and under 
Article 1, Section 8, Clause 8 of the U.S. Constitution.  See, e.g., Diamond v. 
Chakrabarty, 447 U.S. 303, 309 (1980) (“The laws of nature, physical phenomena, 
and abstract ideas have been held not patentable.  Thus, a new mineral discovered 
                                                 
2 Studies of scientists show this argument is not valid.  Many geneticists are willing 
to discover, identify, sequence, and undertake genetic testing without the patent 
incentive.  See, e.g., Isaac Rabino, How Human Geneticists in U.S. View 
Commercialization of the Human Genome Project, 29 Nat. Genetics 15 (2001). 
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in the earth or a new plant found in the wild is not patentable subject matter. 
Likewise, Einstein could not patent his celebrated law that E=mc2; nor could 
Newton have patented the law of gravity.  Such discoveries are ‘manifestations of 
. . . nature, free to all men and reserved exclusively to none.’” (citations omitted)); 
Parker v. Flook, 437 U.S. 584 (1978); Gottschalk v. Benson, 409 U.S. 63, 67 
(1972); Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948); 
O’Reilly v. Morse, 56 U.S. 62, 112-121 (1854); Le Roy v. Tatham, 55 U.S. 156, 
175 (1853); Am. Wood-Paper Co. v. Fibre Disintegrating Co., 90 U.S. (23 Wall.) 
566, 594 (1874).  See also Linda J. Demaine & Aaron Xavier Fellmeth, 
Reinventing the Double Helix: A Novel and Nonobvious Reconceptualization of the 
Biotechnology Patent, 55 Stan. L. Rev. 303 (2002); John M. Conley and Robert 
Makowski, Back to the Future: Rethinking the Product of Nature Doctrine as a 
Barrier to Biotechnology Patents (Part II), 85 J. Pat. & Trademark Off. Soc’y 371 
(2003); John M. Conley, Gene Patents and the Product of Nature Doctrine, 84 
Chi. Kent L. Rev. 3 (2009).  Myriad’s patents improperly claim both products of 
nature and laws of nature.   
A. Gene Sequences are Unpatentable Subject Matter Under 35 
U.S.C. § 101 and Under Article I, Section 8, Clause 8 of the U.S. 
Constitution 
  
Myriad’s patents claim the BRCA1 and BRCA2 breast cancer gene 
sequences.  For example, claim 1 of U.S. Patent No. 5,747,282 claims:  “An 
 15 
isolated DNA coding for a BRCA1 polypeptide, said polypeptide having the amino 
acid sequence set forth in SEQ ID NO:2.”  Myriad’s patents’ specifications state: 
An “isolated” or “substantially pure” nucleic acid (e.g., an RNA, 
DNA or a mixed polymer) is one which is substantially separated 
from other cellular components which naturally accompany a native 
human sequence or protein, e.g., ribosomes, polymerases, many other 
human genome sequences and proteins. The term embraces a nucleic 
acid sequence or protein which has been removed from its naturally 
occurring environment, and includes recombinant or cloned DNA 
isolates and chemically synthesized analogs or analogs biologically 
synthesized by heterologous systems.   
 
U.S. Pats. Nos. 5,693,473; 5,747,282; 5,837,492; 5,709,999; 5,710,001; 5,753,441; 
6,033,857.    
Based on the fact that it has isolated the DNA, i.e. taken it out of the body, 
Myriad’s assignor has patented the DNA.  However, the fact that a gene is 
removed from a cell and its cellular components does not make it patentable 
subject matter under § 101.   Like a “new plant found in the wild,” these gene 
sequences occur naturally in the human body.  These gene sequences were not 
created by man and therefore are not patentable under 35 U.S.C. § 101 and the 
U.S. Constitution. 
 Patents are granted to inventors, not to people who discover a product of 
nature, even if they isolate or purify that product of nature or improve upon it.  In 
Funk Brothers, 333 U.S. at 130, the patent applicant had mixed several types of 
root nodule bacteria capable of inoculating the seeds of plants.  The U.S. Supreme 
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Court held that the mixture was not patentable because the combination of bacteria 
species did not produce a new invention.  The Court stated that “The bacteria 
perform in their natural way.  Their use in combination does not improve in any 
way their natural functioning.  They serve the ends nature originally provided and 
act quite independently of any effort of the patentee.”  Id. at 131.  Similarly, the 
person claiming ownership of an isolated gene is seeking a monopoly on its natural 
functions—the ability of a gene sequence to anneal to its complementary strand 
(which allows diagnosis) and the ability to produce proteins.  
 In American Wood-Paper, 90 U.S. (23 Wall.) at 594, the U.S. Supreme 
Court held further that an isolated and purified product of nature is not patentable 
if the product functions in a way that is not significantly different than what occurs 
in nature, stating: 
There are many things well known and valuable in medicine or in the 
arts which may be extracted from . . . substances.  But the extract is 
the same, no matter from what it has been taken.  A process to obtain 
it from a subject from which it has never been taken may be the 
creature of invention, but the thing itself when obtained cannot be 
called a new manufacture. 
 
Id. at 593-94.   
In the 1931 case of American Fruit Growers, Inc. v. Brogdex Co., 283 U.S. 1 
(1931), the United States Supreme Court invalidated the product claims on oranges 
and other fruit treated with a borax solution because the resulting fruit/boric 
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compound combination was not a manufacture under the 35 U.S.C. § 31, the 
precursor to § 101 of the Patent Act of 1952.  The Court stated: 
Addition of borax to the rind of natural fruit does not produce from 
the raw material an article for use which possesses a new or 
distinctive form, quality, or property.  The added substance only 
protects the natural article against deterioration by inhibiting 
development of extraneous spores upon the rind.  There is no change 
in the name, appearance, or general character of the fruit.  It remains a 
fresh orange, fit only for the same beneficial uses as theretofore. 
 
Id. at 11-12. 
The Court then stated that applying labor to an article does not necessarily 
make the resulting product a manufacture.  “Washing and scouring wool does not 
make the resulting wool a manufacture of wool.  Cleaning and ginning cotton does 
not make the resulting cotton a manufacture of cotton.”  Id. at 12.   
Similarly in Cochrane v. Badische Anilin & Soda Fabrik, 111 U.S. 293 
(1884), the U.S. Supreme Court held that synthetic products that were made to 
function as their natural counterparts functioned were not patentable subject 
matter.  Cochrane involved a synthetic version of a dye that already existed in 
nature (alizarine), but the synthetic version had a brighter hue.  The Court held that 
“calling it artificial alizarine did not make it a new composition of matter, and 
patentable as such, by reason of its having been prepared artificially, for the first 
time, from anthracine, if it was set forth as alizarine, a well known substance.”  Id. 
at 311. 
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Many lower court cases have followed the U.S. Supreme Court precedent 
that isolated and purified products of nature are not patentable.  See, e.g., In re 
Marden (Marden I), 47 F.2d 957 (C.C.P.A. 1931) (purified uranium); In re Marden 
(Marden II), 47 F.2d 958 (C.C.P.A. 1931) (purified vanadium); In re Merz, 97 F.2d 
599 (C.C.P.A. 1938) (purified ultramarine dye); Dennis v. Pitner, 106 F.2d 142 
(7th Cir. 1939) (purified cube plant root); Gen. Elec. Co. v. DeForest Radio Co., 
28 F.2d 641 (3d. Cir. 1928), cert. denied, 278 U.S. 656 (1928) (purified tungsten); 
Ex parte Latimer, Dec. Comm’r Pat. 123 (1889) (purified pine needle fiber).  Even 
with respect to variations on originally patentable inventions, purification is not 
sufficient to make the substance patentable.  See also Aventis Pharma Deutschland 
GmbH v. Lupin, Ltd., 499 F.3d 1293, 1302 (Fed. Cir. 2007) (“Ordinarily, one 
expects a concentrated or purified ingredient to retain the same properties it 
exhibited in a mixture, and for those properties to be amplified when the ingredient 
is concentrated or purified; isolation of interesting compounds is a mainstay of the 
chemist’s art.”).   
The characteristics and function of a gene reside in the gene sequence.  
These characteristics and functions (the active portion of the gene sequence) have 
not been changed in “isolated” DNA.  Similarly, any labor expended by Myriad’s 
assignors in isolating the DNA sequence or isolating the coding region to form 
cDNA does not transform the natural product into a manufacture.  The resulting 
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molecules and genetic sequences are not markedly different than the molecules that 
occur in the body.  Chakrabarty, 447 U.S. at 310.  They are “fit only for the same 
beneficial uses as theretofore,” just as the treated oranges in American Fruit 
Growers did not gain any new functions by the application of the borax.  See Am. 
Fruit Growers, Inc., 283 U.S. at 12. 
B. Correlations Between Gene Sequences and Cancer are 
Unpatentable Subject Matter Under 35 U.S.C. § 101 and Under 
Article I, Section 8, Clause 8 of the U.S. Constitution 
 
Myriad’s patents also improperly contain claims to correlations between 
certain mutations and a higher risk for breast cancer.  Claim 2 of U.S. Patent No.  
6,033,857, for example, claims: “a method for diagnosing a predisposition for 
breast cancer in a human subject which comprises comparing the germline 
sequence of the BRCA2 gene or the sequence of its mRNA in a tissue sample from 
said subject with the germline sequence of the wild-type BRCA2 gene or the 
sequence of its mRNA, wherein an alteration in the germline sequence of the 
BRCA2 gene or the sequence of its mRNA of the subject indicates a predisposition 
to said cancer.”  These correlation patents cover the relationship between the 
presence of a mutation in the BRCA1 or BRCA2 gene and the risk of cancer.  These 
relationships are laws of nature, just like Einstein’s E=mc2 or the law of gravity and 
are not patentable subject matter under 35 U.S.C. § 101 and the U.S. Constitution.   
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Moreover, Myriad’s method claims directed to “comparing” and “analyzing” 
cover the mental process of merely comparing two gene sequences and recognizing 
a difference.  The Supreme Court has held that claims to mental processes are not 
patentable.  “Phenomena of nature, though just discovered, mental processes, and 
abstract intellectual concepts are not patentable, as they are the basic tools of 
scientific and technological work.”  Flook, 437 U.S. at 589 (quoting Benson, 409 
U.S. at 67).  Myriad’s method claims cover a mental process and are not patentable 
subject matter. 
If Myriad had claimed a gene sequencing machine or had claimed a new 
method of sequencing genes, this would be a patentable invention.  Instead, 
Myriad’s method claims rely on someone else’s patented technology and old 
sequencing methods to sequence genes.  Myriad’s claims do not even recite the 
steps (however performed) of obtaining the information for the analysis or 
comparison, and thus cover solely the mental act of recognizing a similarity or a 
difference.  In fact, “䇺㼇㼍㼉㼚㼍㼘㼥㼦㼕㼚㼓䇻㻌㼛㼞㻌䇺㼏㼛㼙㼜㼍㼞㼕㼚㼓䇻㻌㼣㼛㼡㼘㼐㻌㼎㼑㻌㼡㼚㼐㼑㼞㼟㼠㼛㼛㼐㻌㼎㼥㻌㼛㼚㼑㻌㼛㼒㻌
㼛㼞㼐㼕㼚㼍㼞㼥㻌 㼟㼗㼕㼘㼘㻌 㼕㼚㻌 㼠㼔㼑㻌 㼍㼞㼠㻌 㼠㼛㻌 㼙㼑㼍㼚㻌 㼘㼛㼛㼗㼕㼚㼓㻌 㼍㼠㻌 㼠㼔㼑㻌 㼟㼑㼝㼡㼑㼚㼏㼑㻌 㼠㼛㻌 㼐㼑㼠㼑㼞㼙㼕㼚㼑㻌 㼕㼠㼟㻌
㼏㼔㼍㼞㼍㼏㼠㼑㼞㼕㼟㼠㼕㼏㼟㻘㻌 㼛㼞㻌 㼘㼛㼛㼗㼕㼚㼓㻌 㼍㼠㻌 㼠㼣㼛㻌 㼛㼞㻌 㼙㼛㼞㼑㻌 㼠㼔㼕㼚㼓㼟㻌 㼠㼛㻌 㼐㼑㼠㼑㼞㼙㼕㼚㼑㻌 㼕㼒㻌 㼠㼔㼑㼞㼑㻌 㼕㼟㻌 㼍㻌
㼐㼕㼒㼒㼑㼞㼑㼚㼏㼑㻚䇿㻌 㻌㻭㻞㻠㻤㻜㻚㻌 㻌Steps of isolating and sequencing the gene cannot be read 
into the claim, because to do so would violate the prohibition against incorporating 
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claim limitations from the specification.  See Phillips v. AWH Corp., 415 F.3d 
1303, 1314-15 (Fed. Cir. 2005).3   
Moreover, an unpatentable process cannot be transformed into a patentable 
process by adding insignificant extra-solution activity.  See Bilski v. Kappos, 㻝㻟㻜㻌
㻿㻚㻌㻯㼠㻚㻌 㻟㻞㻝㻤㻘㻌 㻟㻞㻟㻜 (2010); Flook, 437 U.S. at 590; In re Grams, 888 F.2d 835, 
839-840 (Fed. Cir. 1989); In re Schrader, 22 F.3d 290, 294 (Fed. Cir. 1994).  The 
“transformation must be central to the purpose of the claimed process.”  In re 
Bilski, 545 F.3d 943, 953 (Fed. Cir. 2008).  㻌
In addition, Myriad’s claimed “process” involves nothing more than a use of 
the BRCA1 and BRCA2 sequences—or small segments of these gene sequences.  
Since the sequences themselves are unpatentable products of nature, Myriad cannot 
obtain a monopoly on their use through a process claim. 
                                                 
3 Myriad relies on Prometheus, Inc. v. Mayo Collaborative Services to argue that 
its method claims involve a transformation.  581 F.3d 1336 (Fed. Cir. 2009), 
certiorari granted, judgment vacated, and remanded, 130 S. Ct. 3543 (2010).  But 
even if the sample-taking step could be read into the claims, the Myriad patents are 
distinguishable from the patent in Prometheus because no drug is administered to 
alter the normal function of the body.   
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CONCLUSION 
The patent-eligibility issue is a “threshold test” before other requirements of 
patent law are applied to the purported invention.  Bilski, 㻝㻟㻜㻌㻿㻚㻌㻯㼠㻚㻌㼍㼠㻌㻟㻞㻟㻜.  The 
starting point for any analysis of patent-eligibility is the question, “What did the 
patent applicant invent?”  See, e.g., U.S. Pat. and Trademark Off., Official Gazette 
Notices, Nov. 22, 2005, Section II.  With respect to the sequence and correlation 
claims, what did Myriad invent?  With respect to the sequence and correlation 
claims, Myriad and its assignor did not invent anything.  Myriad’s patents on the 
BRCA1 and BRCA2 gene sequences and correlations are invalid patents on 
products of nature and laws of nature.  Moreover, they infringe upon the religious 
beliefs of many people who believe in the sanctity of divine creation.  
Consequently, the claims at issue in the case should be invalidated and the District 
Court decision upheld.     
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